Avrobio is tearing up its plans. Rather than push ahead with work on a trio of gene therapies, the biotech has decided to stop development, lay off half its staff and seek buyers interested in its ...

One stock that might be an intriguing choice for investors right now is AVROBIO, Inc. AVRO. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ:AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases and cancer, today announced that it ...

Gene therapy developer Avrobio was on track to begin a pivotal study this year testing its experimental treatment for a rare metabolic disorder. Instead, the company is shelving that therapeutic ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares ...

Avrobio has updated its Fabry disease gene therapy R&D plans in light of the FDA’s conversion of Sanofi’s Fabrazyme to full approval. The conversion deprives Avrobio of the chance to seek accelerated ...

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its ...